Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2024; 15(8): 1078-1091
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1078
Preparation of kakkatin derivatives and their anti-tumor activity
Yu-Ying Jiang, Hui-Hua Dong, Wen-Ting Zhou, Jia-Zi Luo, Xian Wei, Yan-Qiang Huang
Yu-Ying Jiang, Hui-Hua Dong, Wen-Ting Zhou, Yan-Qiang Huang, Guangxi Technology Innovation Cooperation Base of Prevention and Control Pathogenic Microbes with Drug Resistance, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Yu-Ying Jiang, Hui-Hua Dong, Wen-Ting Zhou, Jia-Zi Luo, Xian Wei, Key Laboratory of the Prevention and Treatment of Drug Resistant Microbial Infecting, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Jia-Zi Luo, Collaborative Innovation Center for Guangxi Ethnic Medicine, The School of Chemistry and Pharmaceutical Sciences, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Xian Wei, Research Center for the Prevention and Treatment of Drug Resistant Microbial Infecting, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Co-first authors: Yu-Ying Jiang and Hui-Hua Dong.
Co-corresponding authors: Xian Wei and Yan-Qiang Huang.
Author contributions: Jiang YY and Dong HH were responsible for the experimental research, performed to consult literature, involved in the data collection and analysis, drafted the manuscript, and contributed equally to this work; Zhou WT and Luo JZ contributed new reagents and analytic tools; Wei X and Huang YQ designed, checked and modified finalize the manuscript, and contributed equally to this work; all authors were involved in the critical review of the results and have read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Youjiang Medical University for Nationalities Institution review board.
Conflict-of-interest statement: The authors declare they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Data sharing statement: All data included in this study are available upon request by contact with the corresponding author at 27848258@qq.com.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian Wei, PhD, Professor, Research Center for the Prevention and Treatment of Drug Resistant Microbial Infecting, Youjiang Medical University for Nationalities, No. 98 Countryside Road, Baise 533000, Guangxi Zhuang Autonomous Region, China. 27848258@qq.com
Received: March 21, 2024
Revised: July 20, 2024
Accepted: July 29, 2024
Published online: August 24, 2024
Processing time: 147 Days and 18.6 Hours
Core Tip

Core Tip: We synthesized a new kakkatin derivative [6-(hept-6-yn-1-yloxy)-3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one (HK)] and explored its anti-tumor activity against liver cancer, gastric cancer and its potential mechanism of action. It was found that the synthesized HK increased the anti-hepatoma activity by nearly 30 times compared with kakkatin, but the inhibitory effect on gastric cancer MGC803 cells was not much different from that of kakkatin, indicating that the anti-tumor activity of HK may be more specific. PDE3B and NFKB1 proteins in the cAMP pathway are the targets of the HK on HCC SMMC-7721 cells.